Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors
Titel:
Safety and pharmacokinetic study of RPI.4610 (ANGIOZYME), an anti-VEGFR-1 ribozyme, in combination with carboplatin and paclitaxel in patients with advanced solid tumors
Auteur:
Kobayashi, Hiroyuki Gail Eckhardt, S. Lockridge, Jennifer A. Rothenberg, Mace L. Sandler, Alan B. O’Bryant, Cindy L. Cooper, Wendy Holden, Scott N. Aitchison, Roger D. Usman, Nassim Wolin, Maurice Basche, Michele L.